Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Sanofi India - Results affected by the divestment - ICICI Securities

Posted On: 2020-10-27 22:34:34

Sanofi India's (SANL) Q3CY20 reported a muted performance during the quarter. Revenue declined 11.9% YoY to Rs6.9bn but the base includes business that has been divested alongwith the Ankleshwar plant. Adjusting for it, approximate growth stood at 3.8% YoY. EBITDA margin improved 550bps YoY and 310bps QoQ to 28.0% with lower expenses. Adjusted PAT declined 19.0% to Rs1.3bn. As per AIOCD data, company reported a growth of 4.5% for the quarter. In the past few years, the company's growth and profitability was fuelled by the power brands. We remain positive on SANL considering high visibility of strong growth from its chronic therapy exposure in domestic formulations, strong balance sheet with deep cash reserves, and strong brand equity built over the years. Maintain HOLD with a revised target price of Rs8,731/share.

- Adjusted growth weak; lower costs lift margins: Revenue declined 11.9% YoY, however adjusting the base for the divestment, wherein company transferred the Ankleshwar manufacturing plant and few products to Zentiva, approximate growth stood at 3.8% YoY. It is marginally lower than that of the AIOCD reported growth of 6.3% in the quarter. Transfer of the Ankleshwar plant has caused a sharp decline in expenses. Raw material cost declined 16.9% YoY lifting gross margin 250bps YoY. Staff cost declined 6.3% YoY whereas S,G&A expenses fell sharply by 30.1% YoY. This resulted in 550bps YoY jump in EBITDA margin to 28.0%. On an absolute basis, EBITDA grew 9.5% YoY. However, we expect these expenses to increase and normalise over the next few months alongwith growing domestic revenue.

- Key products performance: As per AIOCD data SANL has reported a growth of 6.3% during the quarter. Lantus, Clexane and Avil have reported YoY growth of 14.1%, 116.8% and 22.8% respectively for the quarter. While Allegra, Amaryl M, Cardace, Enterogermina and Targocid have declined 19.7%, 8.7%, 4.8%, 27.5% and 4.4% YoY respectively. Higher chronic contribution (~54% of domestic sales), which has more inelastic demand as compared to acute therapies, would cushion revenues in the uncertain near-term environment.

- Outlook: We expect revenue/EBITDA/PAT to grow 2.1%/ 6.8%/12.6% over CY19- CY22E with declining export revenue contribution. We expect SANL to improve its return profile and continue generating strong free cash with growing profitability. Rising contribution of domestic revenue would help lift margins gradually.

- Valuations and risks: We reduce our revenue and EPS estimates by 3-4% and 0-3% for CY21E-CY22E to factor in lower sales and expenditure. Maintain HOLD rating with a revised target price of Rs8,731/share based on 33xJun'21E EPS (earlier: Rs8,838). Key downside risks are: addition of key drugs in NLEM, product concentration, government intervention, and presence of unlisted promoter company. Key upside risks are: launch of new products and higher margins with tight cost control measures.

Shares of Sanofi India Ltd was last trading in BSE at Rs.8394.65 as compared to the previous close of Rs. 8315.65. The total number of shares traded during the day was 5580 in over 252 trades.

The stock hit an intraday high of Rs. 8442 and intraday low of 8350. The net turnover during the day was Rs. 46871085.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Auto Sector - Monthly Volume Round-up - Nov 20 - Reliance Securities

What do brokerages say on Burger King India Limited's IPO?

The Phoenix Mills - Potential fund infusion may usher in growth - ICICI Securities

Godrej Agrovet - Beneficiary of 60% increase in palm oil prices - ICICI Securities

Automobiles (wholesale) - Wholesale dispatches rise amidst modest retail trends - ICICI Securities

Oil & Gas - Sector Update - Dec 2020 - ICICI Direct

Phoenix Mills (Buy): Asset monetisation at favourable terms... - ICICI Direct

Aditya Makharia's views on November Auto Sales Number for November 2020 - HDFC Securities

Burger King India - IPO Review - ICICI Direct

Quant Pick - LIC Housing Finance - ICICI Direct

Tech Mahindra - Analyst Meet Update - ICICI Direct

Gladiator Stocks - Crompton Greaves Consumer Electricals - ICICI Direct

Derivatives Monthly Outlook - Nifty support at 12800 for ongoing momentum...

Quant Pick - Sun Pharmaceuticals - ICICI Direct

Monetary Policy - Expectation from YES Securities

Sector Update on Asset Management Companies - Subdued but improvement expected - HDFC Securities

Pre Monetary Policy View - Dec, 2020 - Lakshmi Iyer, President and CIO (Debt) & Head Products, Kotak Mutual Fund

Maintain REDUCE on Siemens - Smart recovery priced in - HDFC Securities

Banking Sector Credit Trends - Growth continues to moderate - HDFC Securities

Q2 FY21 GDP: Light at the end of the tunnel - YES Securities

Siemens - Q4 FY20 Result Update - YES Securities

Super action in Home Loans - SBIN, ICICIBC, AXSB, HDFC and LICHF gaining share - YES Securities

Polymer price tracker - Dec 1, 2020 - PVC prices continue to tread higher - ICICI Securities

Bajaj Finance - Company Update - Dec 2020 - ICICI Direct

Siemens Ltd - Healthy revival in orders and margins - ICICI Securities

Covid Recovery Pulse - Nov 30, 2020 - Festive positivity continues in auto retails, e-way bill generation improves...

Derivatives Weekly View (November 27): Momentum expected to continue in broader markets with Nifty support at 12800...

Derivatives Strategy - Positional Option - ICICI Direct

Preview on RBI Monetary Policy - December 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

10 things you should know about Burger King India Limited

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019